Dapagliflozin improves kidney and cardiac function in cases of FSGS kidney disease: Study Hina Zahid10 Jun 2021 9:00 AM ISTSGLT2 inhibitors offer a promising new therapeutic option in the field of nephrology and are likely to be used more extensively in future, both in...
SGLT2 inhibitors improve biomarkers indicative of CVD risk in diabetes patients: Study Medha Baranwal2 Jun 2021 9:30 AM ISTTurkey: Both dapagliflozin and empagliflozin significantly improve plasma atherogenic biomarkers (AIP and TyG indexes), an indicator of cardiovascular...
Abbott, AstraZeneca terminate agreement for diabetes drug Dapagliflozin in India Ruchika Sharma30 May 2021 10:15 AM ISTNew Delhi: Drug major AstraZeneca Pharma India on Friday said it has terminated its distribution agreements with Abbott Healthcare for type 2 diabetes...
Sun pharma secures trademarks rights of diabetes drug Dapagliflozin under 3 brands from AstraZeneca Ruchika Sharma29 May 2021 5:30 PM ISTNew Delhi: Drug major Sun Pharma on Friday said it has acquired the rights to trademarks of diabetes drug Dapagliflozin under brands Oxra, Oxramet and...
Dapagliflozin Might not Benefit Severe COVID19 Patients: DARE 19 Trial MD Bureau27 May 2021 9:00 AM ISTAlthough the primary action of sodium-glucose cotransporter-2 (SGLT2) inhibitors is on glucose and sodium reabsorption in the proximal convoluted...
Exenatide-Dapagliflozin Combo Enhances Kidney Protection: DECREASE Trial Dr Kartikeya Kohli24 May 2021 7:30 PM ISTSodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1RAs) are common hypoglycemic drugs. Previous...
Dapagliflozin may Improve Diabetic Retinopathy, Finds Study MD Bureau10 May 2021 6:30 PM ISTDiabetic retinopathy (DR) is a leading cause of blindness and vision impairment. In a recent study presented at the Association for Research in Vision...
AstraZeneca Farxiga gets approval in US for CKD prevention Ruchika Sharma2 May 2021 9:30 AM ISTUK: AstraZeneca's Farxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved in the US to reduce the risk of...
FDA Approves dapagliflozin for treating Chronic Kidney Disease Dr Kartikeya Kohli1 May 2021 7:46 AM ISTThe U.S. Food and Drug Administration has approved dapagliflozin oral tablets to reduce the risk of kidney function decline, kidney failure,...
SGLT2 inhibitor dapagliflozin significantly impacts urine metabolome in diabetics: Study Medha Baranwal18 April 2021 2:27 PM ISTGreece: Dapagliflozin treatment is associated with a significant change in urine metabolome in patients with type 2 diabetes (T2D) independent of...
Dapagliflozin Reduces Blood Pressure by Vasodilation, Finds Study MD Bureau25 March 2021 7:58 PM ISTHypertension and type 2 diabetes mellitus (T2DM) are risk factors for cardiovascular disease. Dapagliflozin improves both blood sugar and systolic...
Health Minister discusses side-effects of SGLT-2 inhibitors in the parliament Meghna A Singhania8 Feb 2021 4:10 PM ISTNew Delhi: With the rising incidence of diabetes in the country, SGLT-2 inhibitors have emerged as one of the preferred modality of treatment....
